Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 14/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604032 | 0.90 | PIK3CB (0.51) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3595766 | 0.88 | PIK3CA (0.51) | PIK3CBPIK3CACYP1A2CYP2D6MAPT | |
| SCHEMBL3600948 | 0.81 | PIK3CB (0.54) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL913203 | 0.81 | MAPT (0.49) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3607480 | 0.80 | MAPT (0.51) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3610061 | 0.79 | CYP1A2 (0.56) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3609974 | 0.79 | CYP1A2 (0.52) | PIK3CBPIK3CACYP1A2CYP2D6MAPT | |
| SCHEMBL3598581 | 0.77 | KMT2A (0.48) | PIK3CBHTTPKMTSHRCRHBP | |
| SCHEMBL3596067 | 0.77 | KMT2A (0.48) | PIK3CBHTTPKMTSHRCRHBP | |
| Bromide SCHEMBL3600548 | 0.76 | MAPT (0.49) | PIK3CBHTTPKMTSHRCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | BAKER STEWART JAMES | 2010-10-07 | — | — | US | disclosed |
| WO-2008125833-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256143-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, JAK2 | PIK3CB 9/4885HTT 3450/4885PKM 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.